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S U M M A R Y
Objectives: The aims of this studywere to determine predictive factors of paradoxical reaction in patients
with cervical lymph node tuberculosis (TB) and to discuss the therapeuticmanagement of this condition.
Materials andmethods: A retrospective studywas performed of 501 patientsmanaged for cervical lymph
node TB over a period of 12 years (from January 2000 to December 2011). Statistical data were analyzed
using IBM SPSS Statistics version 20.0.
Results: Paradoxical reaction occurred in 67 patients (13.4%), with a median delay to onset after starting
TB treatment of 7 months. Lymph node size 3 cm and associated extra-lymph node TB were
independently associated with paradoxical reaction. Treatment consisted of surgical excision (71.6%),
restarting quadruple therapy (10.4%), reintroduction of ethambutol (23.8%), and addition of
ciproﬂoxacin (20.8%); steroids were given in two cases . All patients recovered after an average
treatment duration of 14.91  7.03 months.
Conclusion: The occurrence of paradoxical reaction in cervical lymph node TB seems to be predicted by
associated extra-lymph node TB and a swelling size 3 cm. The treatment of paradoxical reaction
remains unclear and more randomized trials are necessary to improve its management.
 2016 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Paradoxical reaction (PR) during tuberculosis (TB) treatment is
deﬁned as a transient worsening of pre-existing clinical and/or
radiological lesions, or as the formation of a new tuberculous
location, during appropriate treatment that is being taken
correctly.1 It occurs in about 20% of patients, with an average
delay to onset of 2 to 3.5 months after the initiation of TB
treatment.2 The delay to occurrence is unpredictable, as are its
duration and severity.
Limited information is available regarding the risk factors of PR
associatedwith peripheral cervical lymph node TB and controversy
remains about its therapeutic management. The aims of this study
were to determine the predictive factors of PR in patients with
cervical lymph node TB and to discuss the therapeutic approaches.
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creativecommons.org/licenses/by-nc-nd/4.0/).2. Materials and methods
Thiswas a retrospective study involving 501 patients diagnosed
with cervical lymph node TB at Rabta Hospital, a tertiary teaching
hospital in Tunis, Tunisia. Patients were managed in the
departments of otorhinolaryngology and infectious diseases over
a period of 12 years (From January 2000 to December 2011).
Lymphadenectomy was performed for diagnosis in 84.8% of cases.
The diagnosis was made by ﬁne-needle aspiration cytology in the
remaining 15.2% of patients. Cases were deﬁned as conﬁrmed
following the identiﬁcation ofMycobacterium tuberculosis in lymph
node and/or another biological ﬂuid. Cases were deﬁned as
probable in the presence of typical histological ﬁndings (granulo-
ma with caseating necrosis), or necrosis on histology with healing
under TB treatment. TB treatment was performed as recom-
mended by the World Health Organization. Four drugs (isoniazid,
rifampicin, ethambutol, pyrazinamide; HRZE) were administered
for 2 months, followed by a two-drug regimen (isoniazid and
rifampicin) for a variable duration. Two major drugs were used in
all cases: isoniazid and rifampicin.ious Diseases. This is an open access article under the CC BY-NC-ND license (http://
Table 2
Predictive factors for paradoxical reaction: multivariate analysis
Variable OR 95% CI p-Value
Extra-lymph node TB 6.510 1.597–3.504 0.003
Node size 1.811 1.060–3.092 0.030
Sweating 1.779 0.792–3.995 0.163
Complications of medical treatment 1.732 0.905–3.392 0.096
Number of lymph nodes 1.468 0.848–2.539 0.170
Fever 0.946 0.402–2.224 0.898
OR, odds ratio; CI, conﬁdence interval; TB, tuberculosis.
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treatment, were transferred to another hospital during treatment,
had incomplete medical records, or were lost during the follow-up
period were excluded.
All tests of signiﬁcance were conducted using IBM SPSS
Statistics version 20.0 software (IBM Corp., Armonk, NY, USA).
Univariate and multivariate analyses were performed using
logistic regression. A p-value of <0.05 was considered statistically
signiﬁcant.
3. Results
Over the study period, 501 patients were diagnosedwith lymph
node TB; 185 were male and 316 were female, giving a sex ratio of
0.37. The median age of the patients was 33 years (interquartile
range (IQR) 21–46 years). HIV testing was performed in only four
cases and was negative. TB was conﬁrmed in four cases and was
probable in 497 cases. A past TB treatment was noted in 14 cases.
The tuberculin skin test (TST) was positive in 77.6% of cases.
PR occurred in 67 patients (13.4%), with amedian delay to onset
after starting TB treatment of 7 months (IQR 4–9 months). The
median age of the patients was 30 years (IQR 21–46 years). The
same female predominance was noted, with a sex ratio of
0.39. Diabetes was noted in three patients, with associated
Henoch-Scho¨nlein [3_TD$DIFF]disease in one case. A past medical history of
treated TB was reported in two cases. Extra-lymph node TB was
found in six cases. All patients reported regular intake of their
medications. Of these patients, 44.8% presented with enlarged
lymph nodes at previous sites. On clinical examination, new lymph
nodes had appeared in 32.8% of patients. Fluctuation andTable 1
Predictive factors for paradoxical reaction: univariate analysis
Variable Number OR 95% CI p-Value
Age 30 years: 35
>30 years: 32
0.746 0.446–1.249 0.265
Sex Male:19
Female:48
1.060 0.598–1.877 0.842
Immunological deﬁciency Yes: 3
No: 64
1.224 0.347–4.321 0.753
Fever Yes: 14
No: 53
1.646 0.860–3.150 0.132
Emaciation Yes: 8
No: 59
1.018 0.460–2.252 0.964
Sweating Yes: 15
No: 52
1.987 1.047–3.770 0.035
Number of lymph nodes Multiple: 42
Single: 25
1.649 0.971–2.801 0.064
Bilateral cervical lymph nodes Yes: 7
No: 60
0.7 0.305–1.061 0.398
Mobility Fixed: 25
Mobile: 42
1.376 0.805–2.352 0.242
Local tenderness Yes: 13
No: 54
1.5 0.772–2.915 0.229
Skin appearance Inﬂammatory: 20
Normal: 47
1.223 0.694–2.154 0.485
Node size 3cm: 34
<3cm: 33
1.232 1.127–3.176 0.016
Consistency Soft: 8
Firm: 59
1.2/32 0.552–2.751 0.609
Extra-lymph node TB Yes: 6
No: 61
4.644 1.597–13.504 0.004
Elevated WBC count Yes: 5
No: 62
4.644 0.604–4.609 0.323
Anemia Yes: 18
No: 49
1.423 0.790–2.564 0.238
Treatment Standard: 57
Combined: 10
1.327 0.650–2.710 0.436
Treatment complications Yes: 15
No: 52
1.735 0.916–3.285 0.090
OR, odds ratio; CI, conﬁdence interval; TB, tuberculosis; WBC, white blood cell.ﬁstulization were observed in 16.4% and 6% of patients, respec-
tively. New bacteriological smears were not performed.
Univariate analysis of predictive factors of PR revealed that
sweating, a lymph node size 3 cm, and associated extra-lymph
node TB were associated with a high risk of PR (Table 1). On
multivariate analysis, a lymph node size 3 cm and associated
extra-lymph node TB were independently associated with PR
(Table 2).
The management of PR varied depending on the case and the
doctors involved (Figure 1). Two patients received systemic
steroids for a large ﬂuctuant swelling, without any improvement.
Quadruple therapy (HRZE) was reinitiated in 10.4% of patients.
Mycobacterium bovis was suspected in 13.4% of patients, and
ethambutol was added to isoniazid and rifampicin. Because of
gastric pain and to avoid optic toxicity, ciproﬂoxacin was added to
the TB treatment in 19.4% of cases (the only oral ﬂuoroquinolone
used at the hospital during that period) (Table 3). Surgical excision
of the lymph node was performed in 71.6% of cases (Figure 2). All
patients recovered after a median duration of TB treatment of
14.91  7.03months. The durationwas signiﬁcantly longer in the PR-
[(Figure_1)TD$FIG]
Figure 1. Therapeutic algorithm for paradoxical reaction in patients with cervical
lymph node tuberculosis.
Table 3
Paradoxical reaction: treatment decision
Treatment Number (%) Treatment duration,
months (IQR)
Steroids
Ciproﬂoxacin
Restarting quadruple therapy
Addition of ethambutol
Surgical excision
Continuation of classic treatment
2 (3%)
13 (19.4%)
7 (10.4%)
9 (13.4%)
48 (71.6%)
2 (3%)
2.5
5 (3–18)
3.87 (3–4)
3.2 (1–9)
IQR, interquartile range.
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8.48 months; p < 0.001). No recurrence was detected in this study.
4. Discussion
Lymph node TB is the most common extra-pulmonary location
of TB. In Tunisia, its prevalence is estimated to be 23–29.9% of all TB
and is increasing.3 [2_TD$DIFF] It is the second most common form after
pulmonary TB.3 With appropriate treatment, the outcome of
lymph node TB is usually favorable, but worsening can occur under
effective treatment, resulting in a PR.4
The pathogenesis of PR remains unclear, but it is probably due
to an immunological response.5 Two different hypotheses have
been put forward. The ﬁrst is that PR is caused by delayed immune
activation. This is supported by the fact that patients with PR
generally have a negative TST and decreased lymphocyte
blastogenesis at the time of diagnosis, but a positive TST and
increased lymphocyte blastogenesis after the initiation of thera-
py.6,7 The second is a hypersensitivity reaction to the antigen
released from dying mycobacteria.2,8,9
The prevalence of PR is variable. It has been reported to occur in
5–35% of patients receiving TB treatment.5 Cheng et al. found that
only 2.4% of pulmonary TB patients developed PR.10 Its prevalence
in lymph node TB seems to be higher, ranging from 12% to 23%.2,3
These differences may be due to the infection site.4 In the present
study, the prevalence of PR was 13.4%.
The diagnosis of PR is not easy since the results of bacteriology
are usually negative, making it difﬁcult to rule out drug resistance.
In the present study, the TST was not performed again to identify
any new positive result. The TST was positive in 73.3% of PR
patients and in 77.9% of the remaining patients, with no difference
between the two groups.
Risk factors for PR during TB treatment have been explored
mainly in HIV-infected patients. However, limited data are
available on the risk factors for PR in immunocompetent patients
with lymph node TB.2
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Figure 2. Therapeuticmanagement of paradoxical reaction in the present series (FQ,
ﬂuoroquinolone).Cheng et al. found that baseline anemia, hypoalbuminemia,
lymphopenia, and a greater change in lymphocyte count were
independent risk factors for developing PR in pulmonary TB.10
Anemia and a lower lymphocyte count at baseline have been
described as biological predictors of PR.11–13 Hawkey et al. found
that a higher peripheral blood monocyte count at baseline might
be predictive of PR in HIV-negative patients with peripheral lymph
node TB.14 Jung et al. concluded that a high baseline albumin level
in serumwas a risk factor for PR in pleural TB.4 In the present study,
neither anemia nor leukocytosis were predictive of PR. No other
biological abnormalities were observed.
Cho et al. and Hawkey et al. found that younger age, male sex,
and local tenderness at the time of diagnosis were independently
associatedwith PR in HIV-negative patients with peripheral lymph
node TB.2,14 Several case–control studies have demonstrated that
PR occurs more frequently in patients with extrapulmonary
involvement.11,12 However, none of the factors have been shown
to be clinically useful to date. In the present study, none of the
biological criteria were associated with PR; only extra-lymph node
TB and a swelling size 3 cm were independent risk factors for
developing PR.
PR is usually a mild, transient, and self-limited phenomenon.
No consensus on the therapeutic management of this entity
has been reached to date, but many authors propose an
extension of TB treatment, a short course of steroids, and
aspiration puncture and/or surgical excision of the lymph node.1
The value of steroid therapy in the management of PR has been
emphasized mainly in cases of intracranial tuberculoma.1,14 Jung
et al. demonstrated an improvement in 71% of patients with PR
in pleural TB after steroid therapy; they found that steroid
responders showed a more rapid improvement than the non-
steroid group.4 Recent studies have suggested that immuno-
therapy with steroids or an anti-tumor necrosis factor alpha
(anti-TNF-a) inhibitor may help to resolve PR by inhibiting
granuloma formation interfering with the penetration of TB
treatment.3,14,15 In the study by Geri et al., the use of adjunctive
steroids in the management of PR was not associated with a
signiﬁcant clinical improvement.13 In the present study, the
number of patients treated with steroids was limited, so
conclusions cannot be drawn.
The surgical approach was adopted in 71.6% of cases in this
study. It is believed that the excision of large lymph nodes and
drainage of cold abscesses could shorten the duration of TB
treatment and improve the healing processes. Surgery was useful
when the PR did not improve 4–8weeks after the adjustment of TB
treatment. Needle aspiration and a prolongation of the TB
treatment is a common alternative to surgical excision, but there
is a higher risk of ﬁstulization or poor wound healing with this
method.12
The main limitation of this study was a lack of positive
culture. Thus drug resistance could not be eliminated. The
diagnosis of PR was made retrospectively when patients healed
after the use of a steroid, surgical treatment, or prolonged TB
treatment.
In conclusion, PR is not uncommon in patients with cervical
lymph node TB. Its occurrence seems to be predicted by
associated extra-lymph node TB and a swelling size 3 cm.
Resorting to surgery to shorten the course of medical treatment
will hinder the clariﬁcation of a strategy for the management of
treatment. Randomized trials are required to determine the
pathogenesis of PR and improve its management in cervical
lymph node TB.
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